Drugs / NEU-627
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06900751 | Jun → Oct 2025 | — | Neuron23 Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-03-25 | Neuron23 Inc. | Results Neuron23 Announces Publication in PNAS Highlighting the Important Role of TYK2 in Neuroimmunology neuron23.com ↗
The manuscript highlights multiple nonclinical studies utilizing one of Neuron23’s selective, brain-penetrant small molecule TYK2 inhibitors, which demonstrated a significant impact on disease in EAE, a dampening of microglial and astrocytic activation, and a resulting reduction in harmful downstream cytokines, chemokines, and markers of neurodegeneration/de-myelination. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-03-25 | Neuron23 Inc. | Neuron23 Announces Publication in PNAS Highlighting the Important Role of TYK2 in Neuroimmunology neuron23.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEU-627 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06900751 ↗ |